These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 10156421

  • 1. Deterring inefficient pharmaceutical litigation: an economic rationale for the FDA regulatory compliance defense.
    Viscusi WK, Rowland SR, Dorfman HL, Walsh CJ.
    Spec Law Dig Health Care Law; 1996 Mar; (205):9-52. PubMed ID: 10156421
    [No Abstract] [Full Text] [Related]

  • 2. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
    Gitter DM.
    Seton Hall Law Rev; 2011 Mar; 41(2):559-92. PubMed ID: 21739759
    [No Abstract] [Full Text] [Related]

  • 3. FDA cracks down on labeling, initiates trial result reporting.
    Osborne R, Waltz E.
    Nat Biotechnol; 2008 Nov; 26(11):1203-4. PubMed ID: 18997742
    [No Abstract] [Full Text] [Related]

  • 4. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry.
    Karst KR.
    Am Univ Law Rev; 2000 Nov; 49():739-72. PubMed ID: 11067732
    [No Abstract] [Full Text] [Related]

  • 5. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM, Curry JA.
    Tort Trial Insur Pract Law J; 2007 Nov; 43(1):35-70. PubMed ID: 18354866
    [No Abstract] [Full Text] [Related]

  • 6. US lawmakers tackle safety reforms at the FDA.
    Zwillich T.
    Lancet; 2007 Jun 16; 369(9578):1989-90. PubMed ID: 17577942
    [No Abstract] [Full Text] [Related]

  • 7. Bolstering the FDA's drug-safety authority.
    Schultz WB.
    N Engl J Med; 2007 Nov 29; 357(22):2217-9. PubMed ID: 18046024
    [No Abstract] [Full Text] [Related]

  • 8. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
    O'Reilly JT.
    Food Drug Law J; 2007 Nov 29; 62(3):559-72. PubMed ID: 17915397
    [No Abstract] [Full Text] [Related]

  • 9. FDA prohibits extralabel use of two drug classes.
    J Am Vet Med Assoc; 1997 Aug 01; 211(3):269. PubMed ID: 9262656
    [No Abstract] [Full Text] [Related]

  • 10. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL.
    J Natl Cancer Inst; 2005 Jun 15; 97(12):872-3. PubMed ID: 15956645
    [No Abstract] [Full Text] [Related]

  • 11. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR, Ning YM, Farrell A, Justice R, Keegan P, Pazdur R.
    J Natl Cancer Inst; 2011 Apr 20; 103(8):636-44. PubMed ID: 21422403
    [Abstract] [Full Text] [Related]

  • 12. PLIVA v. Mensing: generic consumers' unfortunate hand.
    Lee SB.
    Yale J Health Policy Law Ethics; 2012 Apr 20; 12(2):209-63. PubMed ID: 23175916
    [No Abstract] [Full Text] [Related]

  • 13. FDA perspectives on supplement use by patients on antithrombotic therapy: dietary supplement regulatory overview.
    Woo JJ.
    Thromb Res; 2005 Apr 20; 117(1-2):193-6; discussion 201-7. PubMed ID: 16253311
    [No Abstract] [Full Text] [Related]

  • 14. Legal implications of pharmacogenomics regarding drug trials, drug labeling, and genetic testing for drug prescription: an international approach.
    Mandry T.
    Food Drug Law J; 2004 Apr 20; 59(4):519-35. PubMed ID: 15875348
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. FDA regulatory compliance reconsidered.
    Tobias C.
    Cornell Law Rev; 2008 Jul 20; 93(5):1003-38. PubMed ID: 18618969
    [No Abstract] [Full Text] [Related]

  • 17. Regulatory considerations for determining postmarketing study commitments.
    Meyer RJ.
    Clin Pharmacol Ther; 2007 Aug 20; 82(2):228-30. PubMed ID: 17538552
    [Abstract] [Full Text] [Related]

  • 18. Postmarketing surveillance for oncology drugs.
    Viale PH, Moore S.
    Clin J Oncol Nurs; 2008 Dec 20; 12(6):877-86. PubMed ID: 19064381
    [Abstract] [Full Text] [Related]

  • 19. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
    Consum Rep; 2006 Jan 20; 71(1):34-9. PubMed ID: 16491527
    [No Abstract] [Full Text] [Related]

  • 20. FDA Modernization Act: implications for oncology.
    Morris L.
    Oncology (Williston Park); 1998 Nov 20; 12(11A):139-41. PubMed ID: 10028506
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.